Patents by Inventor Heidrun Engler
Heidrun Engler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8022044Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.Type: GrantFiled: April 13, 2009Date of Patent: September 20, 2011Assignee: Canji, Inc.Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Publication number: 20110104118Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.Type: ApplicationFiled: October 26, 2010Publication date: May 5, 2011Applicant: Canji, Inc.Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
-
Publication number: 20100028431Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.Type: ApplicationFiled: April 13, 2009Publication date: February 4, 2010Applicants: Canji Inc.,, Schering Corporation,Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Patent number: 7538093Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.Type: GrantFiled: February 21, 2006Date of Patent: May 26, 2009Assignees: Schering Corporation, Canji, Inc.Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Patent number: 7534769Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.Type: GrantFiled: January 22, 2002Date of Patent: May 19, 2009Assignees: Canji, Inc., Schering CorporationInventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Publication number: 20090048148Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.Type: ApplicationFiled: March 28, 2008Publication date: February 19, 2009Applicant: Canji, IncInventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
-
Patent number: 7462351Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.Type: GrantFiled: May 25, 2006Date of Patent: December 9, 2008Assignees: Canji, Inc., Innovata LimitedInventors: Susan E. Conroy, Heidrun Engler, Daniel C. Maneval
-
Publication number: 20060199782Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.Type: ApplicationFiled: February 21, 2006Publication date: September 7, 2006Applicants: Canji, Inc., Schering CorporationInventors: Heidrun Engler, Tattanahalli Nagabhushan, Stephen Youngster
-
Patent number: 7002027Abstract: The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene formulated in a buffer comprising a delivery-enhancing agent. The delivery-enhancing agents of the invention can be used to formulate therapeutic or diagnostic agents, such as proteins, nucleic acids, antisense RNA, small molecules, etc., for administration to any tissue or organ having an epithelial membrane. The delivery-enhancing agents include detergents, alcohols, surfactants and other molecules.Type: GrantFiled: July 8, 1997Date of Patent: February 21, 2006Assignees: Canji, Inc., Schering CorporationInventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Publication number: 20050025742Abstract: Methods and pharmaceutical compositions for administering protein or gene therapy to tissues or organs having an epithelial cell layer are provided. A protein or nucleic acid encoding the protein is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the delivery of the interferon or nucleic acid to the cells of the target tissues or organs. The methods and combinations are particularly useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an alpha-interferon or a gene delivery system encoding the interferon and SYN3 or a SYN3 homolog or analog.Type: ApplicationFiled: June 4, 2004Publication date: February 3, 2005Applicant: Canji, Inc.Inventors: Heidrun Engler, Tattanahalli Nagabhushan, Stephen Youngster, Robert Connor
-
Publication number: 20050014259Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.Type: ApplicationFiled: August 6, 2004Publication date: January 20, 2005Inventors: Susan Conroy, Heidrun Engler, Daniel Maneval
-
Publication number: 20040014709Abstract: Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.Type: ApplicationFiled: June 4, 2003Publication date: January 22, 2004Applicant: Canji, Inc.Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Youngster
-
Publication number: 20030211598Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.Type: ApplicationFiled: June 3, 2003Publication date: November 13, 2003Applicant: CANJI, INC.Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
-
Publication number: 20020111502Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.Type: ApplicationFiled: January 22, 2002Publication date: August 15, 2002Applicant: Canji, Inc.Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Publication number: 20020081736Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.Type: ApplicationFiled: November 1, 2001Publication date: June 27, 2002Inventors: Susan E. Conroy, Heidrun Engler, Daniel C. Maneval
-
Patent number: 6392069Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.Type: GrantFiled: July 8, 1998Date of Patent: May 21, 2002Assignee: Canji, Inc.Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
Patent number: 6312681Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol.Type: GrantFiled: September 26, 1997Date of Patent: November 6, 2001Assignee: Canji IncorporatedInventors: Heidrun Engler, Dan Maneval -
Publication number: 20010006946Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.Type: ApplicationFiled: July 8, 1998Publication date: July 5, 2001Inventors: HEIDRUN ENGLER, TATTANAHALLI L. NAGABHUSHAN
-
Patent number: 6165779Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.Type: GrantFiled: January 7, 1997Date of Patent: December 26, 2000Assignee: Canji, Inc.Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
-
Patent number: 5182294Abstract: A new imidazolyl propyl guanidine derivative corresponding to formula I ##STR1## is described, which is distinguished by a combination of particularly advantageous properties for the treatment of diseases of the heart and circulation.Type: GrantFiled: January 10, 1991Date of Patent: January 26, 1993Assignee: Heumann Pharma GmbH & Co.Inventors: Peter Morsdorf, Heidrun Engler, Helmut Schickaneder, Kurt-Henning Ahrens